NCT05122754View on ClinicalTrials.gov

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

February 28, 2024

Study Completion Date

April 28, 2024

Conditions
HIV-1-infection
Interventions
DRUG

B/F/TAF

Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.

DRUG

TDF-based triple ART regimen switching to B/F/TAF

Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.

Trial Locations (3)

201508

Shanghai Public Health Clinical Center, Shanghai

Unknown

Yunnan AIDS Care Center, Kunming

Xixi hospital of Hangzhou, Hangzhou

All Listed Sponsors
collaborator

Xixi Hospital of Hangzhou

UNKNOWN

collaborator

Yunnan AIDS Care Center

OTHER

lead

Shanghai Public Health Clinical Center

OTHER_GOV

NCT05122754 - Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection | Biotech Hunter | Biotech Hunter